The Role of the Financial Adviser in Valuing Pharmaceutical Industry Intellectual Property
November 1, 2005
Robert Schweihs, ASA
Michel St. Martin
The commercial development of a new prescription drug is an extremely costly and highly risky endeavor. Estimating the value of the new prescription drug intellectual property is also a difficult task.
In a pharmaceutical industry product development ...